Dr. Sara M. Tolaney on Neoadjuvant Treatment Considerations for TNBC

Sara M. Tolaney, MD, MPH, medical oncologist, Dana-Farber Cancer Institute, discusses neoadjuvant treatment considerations for patients with triple-negative breast cancer (TNBC).

Sara M. Tolaney, MD, MPH, medical oncologist, Dana-Farber Cancer Institute, discusses neoadjuvant treatment considerations for patients with triple-negative breast cancer (TNBC).

Related Content:

VideosBreast Cancer
Distinct Mechanism of Action Makes Plinabulin a Potentially Powerful Therapy in Treating Breast Cancer
Antibiotic Overuse During COVID-19 Pandemic Exacerbates Need for Firmer Prescription Policies, Expert Says
Antibiotic Market Fails to Protect Patients with Cancer, Expert Says